Seaport Therapeutics, Inc. (NasdaqGS: SPTX)
Health Care · Pharmaceuticals · US
$24.31
+0.37% today · +22.1% 1Y
Seaport Therapeutics, Inc. (NasdaqGS: SPTX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.30B and employs 58 people.
Over the last twelve months the share price has gained 22.1%, trading between 14.85 and 24.48.
SPTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.30B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -11.64
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $24.48
- 52-week low
- $14.85
- Avg volume (3M)
- —
- Shares outstanding
- 53.53M
- Employees
- 58
- Next earnings
- —
About Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
- Founded
- 2024
- Listed since
- May 1, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.